Tauro-β-muricholic Acid (sodium salt) – 5 mg

Brand:
Cayman
CAS:
145022-92-0
Storage:
-20
UN-No:
Non-Hazardous - /

Tauro-β-muricholic acid (TβMCA) is a competitive and reversible antagonist of the farnesoid X receptor (FXR; IC50 = 40 µM) and a taurine-conjugated form of the murine-specific primary bile acid β-muricholic acid (Item No. 20287).{33771} TβMCA accumulates in germ-free mice under normal conditions but is reduced after colonization with feces from a human donor.{33771,33772} TβMCA is increased in the intestines of mice resistant to high-fat diet-induced obesity, fatty liver, and diabetes.{33770}  

 

Available on backorder

SKU: 20289 - Category:

Description

An FXR receptor antagonist (IC50 = 40 µM); a taurine-conjugated form of the murine-specific primary bile acid β-muricholic acid; is reduced in mice after colonization with feces from a human donor; increased in the intestines of mice resistant to high-fat diet-induced obesity, fatty liver, and diabetes


Formal name: 2-[[(3α,5β,6β,7β)-3,6,7-trihydroxy-24-oxocholan-24-yl]amino]-ethanesulfonic acid, monosodium salt

Synonyms:  Tauro-β-muricholate|TβMCA

Molecular weight: 537.7

CAS: 145022-92-0

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Endocrinology & Metabolism|Bile Acids & Microbiome||Research Area|Endocrinology & Metabolism|Hormones & Receptors|FXRs & LXRs||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|NAFLD & NASH||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity